A Functional Role for Antibodies in Tuberculosis

October 6, 2016

Authors: Lu, Lenette L. et al. Cell, Volume 167, Issue 2, 433 - 443.e14

Journal: Cell Press

Journal Abstract/ Summary: While a third of the world carries the burden of tuberculosis, disease control has been hindered by a lack of tools, including a rapid, point-of-care diagnostic and a protective vaccine. In many infectious diseases, antibodies (Abs) are powerful biomarkers and important immune mediators. However, in Mycobacterium tuberculosis (Mtb) infection, a discriminatory or protective role for humoral immunity remains unclear. Using an unbiased antibody profiling approach, we show that individuals with latent tuberculosis infection (Ltb) and active tuberculosis disease (Atb) have distinct Mtb-specific humoral responses, such that Ltb infection is associated with unique Ab Fc functional profiles, selective binding to FcγRIII, and distinct Ab glycosylation patterns. Moreover, compared to Abs from Atb, Abs from Ltb drove enhanced phagolysosomal maturation, inflammasome activation, and, most importantly, macrophage killing of intracellular Mtb. Combined, these data point to a potential role for Fc-mediated Ab effector functions, tuned via differential glycosylation, in Mtb control.

June 3, 2025
The World Vaccine Congress Europe 2025
June 2, 2025
Festival of Biologics
June 1, 2025
The Fc-Mediated Effector Function Summit
May 31, 2025
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
May 31, 2025
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
May 12, 2025
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
By Abigail Harris October 8, 2024
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
October 1, 2024
Authors: P. Hsueh, M. Friedman, S. Jatiani (2024) Application Note
August 1, 2024
Authors: SeromYx Team (2024) White Paper
More Posts →